

Beyond Potential

The Realities and Future of Iran's Pharmaceutical Industry



The First
Edition
2024

www.Iranexpofair.com

 **IRAN
EXPO**

Beyond Potential: The Realities and Future of Iran's Pharmaceutical Industry

- **Prepared for:** Trade and Promotion Organization of Iran (www.TPO.ir)
Iran Expo 2024 Exhibition (www.Iranexpofair.com)
- **Prepared by:** Spark Technology Company (www.sparktechnology.ir)
- **Date:** March, 2024
- **Edition:** The First
- **Executive Summary:** Unveiling the exciting potential of Iran's burgeoning pharmaceutical industry, this report delves into the key strengths driving its growth. These strengths include robust research capabilities, advanced infrastructure, and a relentless focus on innovation. The report identifies specific areas with high growth potential. We provide an overview, examining Iran's strong foundation within the global health industry.

Additionally, we highlight some prominent Iranian pharmaceutical companies, empowering potential partners seeking collaboration to capitalize on the remarkable opportunities within Iran's pharmaceutical landscape.



Trade Promotion Organization of Iran

Contents

03 Introduction	09 Iran's Health Sector
04 Structure of the Report	25 International Regulatory Frameworks
05 Report Specifications	27 Some Iranian Prominent Companies in Pharmaceutical Industry
06 An Overview of Iran	38 References

Introduction

Iran, a nation steeped in history and cultural richness, boasts a burgeoning health industry poised for significant growth. This dynamic sector, embedded within a rapidly evolving economy, presents a compelling picture of potential and capability.

Standing at the crossroads of East and West, Iran leverages its unique position to combine a rich heritage of medical knowledge with cutting-edge advancements. This strategic location fosters a diverse talent pool and facilitates collaboration with both Eastern and Western partners. Furthermore, Iran's vast reserves of natural resources provide the foundation for a robust pharmaceutical industry, while its well-established scientific community fuels research and development efforts.

This report delves into the heart of Iran's healthcare potential, exploring the strengths and resources that position the country as a major player in the global market. We will meticulously analyze the factors that contribute to Iran's competitive edge, including its highly skilled medical professionals, advanced medical infrastructure, and commitment to innovation.

Specific areas within the healthcare sector with high growth potential will be identified, highlighting opportunities for domestic and international collaboration.

This in-depth analysis will serve as a valuable resource for businesses, policymakers, and investors seeking to explore the untapped potential of the Iranian healthcare market.


As we delve deeper, you will gain a comprehensive understanding of the factors shaping the future of healthcare trade and collaboration within this dynamic nation.

This report was prepared with the support of the promotion organization of Iran (TPO). The TPO stands as a pivotal force in fostering trade between Iran and other nations. Established in 1966, it carries the crucial mission of promoting and developing Iran's non-oil trade through a comprehensive set of initiatives. The TPO role extends far beyond simply being a mediator. It actively engages in various endeavors to cultivate a thriving trade environment.

Iran Expo Exhibition is one of the TPO plan to facilitate trading with Iran. Iran Expo is a global platform dedicated to showcasing the achievements and exceptional products of Iran, held in Tehran, serves as a bridge, connecting the world with the rich heritage and dynamic industries of this captivating nation.



Structure of the Report



Report Specifications

Mission of the Report

Empowering Iran's Medicine and Healthcare industry for Global Excellence is the main mission of this report. This mission is driven by a commitment to:

- Access to critical market insights
- Direct Access to Potential Partners
- Establish Valuable and Strategic Connections
- Minimize trade Risks

Purpose of the Report

The primary purpose of this report is to serve as a comprehensive resource for foreign businesses and investors interested in exploring export opportunities in Iran's Medicine and Healthcare industry. It aims to provide a holistic understanding of the sector current status, strengths, opportunities, challenges, and future prospects.

Scope of the Report

The report encompasses a broad scope, covering various aspects of the Iranian Medicine and Healthcare industry export potential. It delves into the following key areas:

- Key Export Products
- The most Attractive Target Markets
- Trade Promotion and Investment Opportunities
- Industry Challenges

Research Methodology

This report analyzes the export potential of Iran's Medicine and Healthcare industry for international traders. It employs a three-step approach:

- **Macroeconomic Analysis:** Data on Iran's GDP, trade volume, and major trading partners was gathered from reputable sources such as the World Bank, International Monetary Fund, and International Trade Center (ITC). This data was analyzed to draw a big picture of the overall economic landscape, highlighting market size, growth potential, and relevant consumer trends.

- **Industry-Specific Research:** Information on Iran's Medicine and Healthcare industry exports, key product categories, and major competitors was collected from specialized databases like Trade Map, FAOSTAT, and COMTRADE. Based on this data, specific Medicine and Healthcare industry segments with high export potential were identified for further study.
- **Primary Data Collection & Company Profiling:** Semi-structured interviews were conducted with representatives of prominent Iranian Medicine and Healthcare industry export companies within the chosen segments. Company Profiles were created for key players, highlighting their strengths, target markets, and export capabilities.

Limitations

It is important to acknowledge that this study has limitations. Access to certain primary data, particularly within specific industry segments, might be restricted due to market competitiveness or data availability. Additionally, the dynamic nature of the global economy and trade regulations necessitates continuous updates to maintain the report accuracy.

Target Audience

The report is primarily tailored to foreign businessmen and investors seeking opportunities to collaborate or invest in Iran's Medicine and Healthcare industry. It aims to cater to a diverse range of stakeholders, including:

- Medicine and Healthcare industry producers and processors
- Medicine and Healthcare industry technology companies
- Investment firms and financial institutions
- Consulting firms and advisors



An Overview of Iran

Iran at a Glance

- Area: 1,648,195 square kilometers
- Population: 88,860,005 people
- Capital: Tehran
- Official religion: Islam
- Official language: Farsi (Persian)
- Currency: Rial
- Number of provinces: 31
- Number of industrial parks: 824
- Number of science & technology parks: 54
- Number of technology incubators: 264
- Number of high-tech companies: 9620
- Number of industrial companies: 30400
- Number of universities: 2183
- Number of ports: 12
- 2023 GDP: 368 billion USD
- The export volume in 2023: 81 billion USD
- The import volume in 2023: 59 billion USD

Iran boasts a rich history and a strategic location, fostering a dynamic and diverse economy. This report delves into the nation's flourishing industries, showcasing its vast potential for international collaboration and growth. With a skilled workforce and a strong entrepreneurial spirit, Iran is poised to play a significant role in the global marketplace. Iran's economy is underpinned by a robust mix of industries. This report explores the strengths of each sector. Iran possesses a strategic location and well-developed infrastructure, making it a key player in international trade. This report examines the country's trade landscape, showcasing the opportunities for foreign businesses to partner with Iranian companies and reach new markets.

GDP

Exhibit 1 shows the GDP (current USD) of Iran from 2010 to 2028, with projections for 2023 to 2028. The GDP is a measure of the total value of goods and services produced within a country in a given period. The graph shows that the GDP of Iran has been growing steadily in recent years, with an average annual growth rate of around 2%.

In 2022, the GDP of Iran was estimated to be around 414 billion USD. Exhibit 1 shows the forecast for Iran's GDP growth between 2023 and 2028 is for modest growth, in the range of 2% to 3% per year. This means that the Iranian economy is expected to grow slowly but steadily over the next few years.

Exhibit 1: GDP (USD) of Iran from 2010 to 2028

(Source: World Bank)



Exchange Rate

The Iranian Rial has weakened against the US dollar in recent years. This weaker exchange rate, meaning more rials are needed per dollar, can make Iranian exports cheaper on the global market.


This could potentially lead to increased demand and production due to lower labor costs (in dollar terms) and a decrease in the unit cost of goods.

Trade Statistics

Iran's overall import statistics have experienced an approximate growth of 40% during the last four years.

Iran's largest imports in 2022 are from the United Arab Emirates (UAE) accounting for 30.7%, followed by China at 26.5%, Turkey at 10.4%, and India at 4.6%.

Exhibit 2: Value of Iran's Export and Import from 2018 to 2022 (Source: TRADE MAP)



Iran's overall export statistics are also going through an upward trend, especially in the last two years. Exports from 2020 to 2022 have grown by 100 percent. Iran's largest export in 2022 is to China with 27.7%.

The reason for the drop in exports in 2019 is the withdrawal of the United States from the JCPOA signed by Donald Trump, the former president of this country, and the return of sanctions in 2018, which resulted in a significant drop in Iran's oil exports.

This trend reached its lowest level in 2020 regarding the impact of the Corona pandemic. After that and under the same conditions, Iran was able to increase its exports.

Iran's Health Sector

The healthcare industry, as one of the important and vital areas in any society, plays a very important role in improving the quality of people's lives and economic development. Medical knowledge in Iran has a long history and has trained many skilled scientists and physicians throughout history who have had a profound impact on the advancement of human knowledge. In ancient times, great figures such as «Abu Ali Sina» and «Zakariya Razi» were born in this land.

In modern times, prominent figures such as «Professor Samii» (the world's best brain surgeon) and Professor «Movahedi» (the world's best heart surgeon) have also been raised here.

Key Factors of Iran's Health Sector

Iran's health sector is positioned for growth and international collaboration, fueled by a robust foundation of strengths.

This report explores these key advantages, highlighting the skilled workforce, commitment to self-sufficiency, and strategic government support that drive innovation and position Iran as a competitive player in the global health market. Among the strengths of Iran, the following can be mentioned:

- **Human Capital:** Iran boasts a large pool of highly trained medical professionals, including doctors, pharmacists, researchers, and scientists. This strong human capital base fuels innovation and research and development (R&D) in the health sector.
- **Focus on Self-Sufficiency:** Iran has prioritized self-sufficiency in healthcare, leading to the development of a robust domestic pharmaceutical industry capable of producing a wide range of essential and generic medications.
- **Government Support:** The Iranian government recognizes the importance of the health sector and invests in R&D initiatives, infrastructure development, and promoting domestic production of medical products.
- **Competitive Advantage:** Iranian medical products are often competitively priced due to lower production costs compared to some international counterparts.
- **Growing Domestic Market:** Iran's large and growing population creates a strong domestic market for pharmaceuticals and medical devices, fostering continuous development within the industry.



- **Advancements in R&D:** Iranian researchers and companies are actively engaged in R&D, developing innovative medical technologies and generic drugs.
- **Focus on Specialties:** Iran has established expertise in specific areas like biopharmaceuticals, herbal medicines, and Nano medicine.
- **Patent Activity:** The increasing number of patents registered by Iranian entities in the medical field demonstrates the country's growing technological capabilities.

In the continuation of the report will examine specific examples within the health sector, providing concrete evidence to support the claims made about Iran's strengths and technological advancements. This will give a more comprehensive picture of what Iran has to offer in the global healthcare landscape.


Iran's Health Status

Exhibit 3 displays the Universal Health Coverage (UHC) effective coverage index for various countries worldwide. Iran presently offers over 70% of the essential and impactful health and treatment services.

The concluding part of this text emphasizes the bright future of Iran's health sector due to the strong foundation it possesses. However, simply stating the potential isn't enough. To truly showcase Iran's capabilities, we need to delve deeper.

This index aims to represent how well health services cover a population's needs and the impact these services have on improving overall health. It considers factors like Accessibility, Quality, and Affordability.


Exhibit 3: Universal Health Coverage Illustration in 2021 (Source: IHME)



A report by the Institute for Health Metrics and Evaluation (IHME) predicts a dramatic shift in Iran's healthcare landscape by 2050.

Government health coverage is expected to more than double, exceeding 100% growth compared to 2019. This translates to a significant decrease in out-of-pocket expenses for citizens, with a projected 4% reduction.


Exhibit 4: Health Coverage in Iran (Source: IHME)



In 2020, according to the World Bank report, Iran's health expenditure per capita reached 573 US dollars, reflecting a significant increase from 94 US dollars in 2001.

This translates to an average annual growth rate of 10.76%. This data highlights Iran's growing investment in healthcare, prioritizing the well-being of its citizens.

Exhibit 5: Health Expenditure per Capita (current USD) in Iran (Source: World Bank)



Iran's Health Sector Workforce

- **311,121 Paramedical personnel**
52,050 Physicians
 - 17,433 General practitioners
 - 4,683 Dentists
 - 304 PhDs in laboratory sciences
 - 2,623 Pharmacists
 - 17,967 Medical specialists
 - 2,553 Subspecialists
 - 6,497 PhDs in specialized fields

(Source: Statistical Center of Iran)

Iran's Health Sector Infrastructure

- Total number of hospitals: 1,020
 - Public hospitals: 705
 - Non-public hospitals: 315
- Number of active comprehensive health service centers: 5,881
- Number of active health bases: 5,535
- Number of active health houses: 17,821
- Number of medical diagnostic laboratories: 4,680
- Number of genetic diagnostic laboratories: 128
- Total number of active pharmacies: 13,052
- Number of veterinary pharmacies: 2,330
- Number of private veterinary clinics: 2,058

(Source: Statistical Center of Iran)

Due to Statista, in 2024:

- Estimated number of hospital beds per 1,000 inhabitants: 1.54
- Estimated number of beds per hospital: 131.10 (assuming even distribution across hospitals)
- Number of physicians: 52,050 (as per your previous translation)
- Number of nurses per 1,000 inhabitants: 2.03
- Number of dentists per 1,000 inhabitants: 0.54
- Number of physiotherapists per 100,000 inhabitants: 14.86

It's important to consider that these are estimates and may not reflect the exact situation in every region of Iran. The number of beds per hospital is an estimate based on the total number of beds and hospitals and may not be representative of every hospital.

Scientific and Technological Potential and Opportunities in Iran

Iran boasts a strong position in medical science according to reputable international organizations. The country ranks 17th globally and 1st in the Middle East and North Africa (MENA) region for its overall medical knowledge. This accomplishment is further supported by Iran's 16th place in the world for publishing medical research. However, Iran's performance is even more impressive in specific medical fields. For instance, Iran ranks a remarkable 4th globally in infertility treatment, solidifying its leading position within the MENA region.

Healthcare Research: Over the past three years, 12 Iranian researchers in the field of health have had an h-index of over 40. This indicates a high level of research productivity in the Iranian healthcare sector.

Scientific Publications: There are currently 53 scientific and research journals in the fields of health and hygiene, 180 journals in the fields of medical sciences, 20 journals in the fields of pharmacy, and 14 journals in the fields of paramedical sciences that are approved by the Ministry of Science and Health. This shows a strong commitment to scientific publishing in the Iranian healthcare sector.

Education and Training: In the field of health sciences, there are numerous universities in Iran that offer admission, education, and training for students in various fields, including medicine, dentistry, pharmacy, paramedical sciences, nursing and midwifery, veterinary medicine, biology, rehabilitation and social health, and health and safety. A total of 67 universities and medical schools are active in Iran. This indicates a well-developed healthcare education system in the country.

Knowledge-Based Companies: The number of knowledge-based companies in Iran has reached 9620 by 2023, showing a 17% growth compared to the previous year. Of these, more than 1600 companies operate in the healthcare sector. 30% of knowledge-based companies in the healthcare sector are active in the field of pharmaceutical raw materials, and 24% are involved in the production of medical equipment. This demonstrates the growing importance of the healthcare sector in Iran's knowledge-based economy.

Science and Technology Parks: There are 13 science and technology parks and 95 technology incubator centers in the field of health. This shows a strong infrastructure for innovation and technology transfer in the Iranian healthcare sector.

Licensed Products and Patented Inventions: Iranian scientists and companies are making significant strides in healthcare innovation, as evidenced by the impressive number of patents they've secured – nearly 180 – with the US Patent and Trademark Office (USPTO) and the European Patent Office (EPO).

This surge in intellectual property protection reflects a broad range of advancements across various healthcare fields including Pharmaceuticals (81 patents), Medical Equipment (162 Patents), Biotechnology (27 Patents), Herbal Plants and Medicine (9 patents).

This surge in innovation signifies several positive developments:

- **Scientific Prowess:** The high number of patents demonstrates the strength of Iranian scientific research and development in the healthcare sector.
- **Global Recognition:** Securing patents in prestigious international offices like USPTO and EPO highlights the global significance of Iranian healthcare advancements.
- **Economic Potential:** These patents have the potential to attract foreign investment, foster the growth of Iranian healthcare companies, and create new jobs within the sector.
- **Improved Healthcare:** Ultimately, these innovations offer the potential to improve the quality of healthcare available not only in Iran but potentially worldwide

Spotlight on Iran's Health Sector

Cell Therapy: Iran has been utilizing cell therapy for nearly two decades, placing it among the top 10 countries to implement this technology. While many nations are still in the research phase, Iran has successfully applied stem cells in various transplants, including cornea, heart, and skin.

Infertility Treatment: Iran stands out as a leading and highly capable nation in assisted reproductive technologies. Royan Infertility Clinic holds the distinction of being Iran's most reputable and well-equipped center for infertility treatment.

Royan not only provides services through specialized centers for infertility, cell therapy, and diabetes, but also actively engages in research through dedicated institutes focused on reproductive sciences, cell and stem cell biology, and biotechnology.

Biotechnology: Iran is now one of the top three producers of biotechnological products in the world. The country produces vaccines for hepatitis B, erythropoietin, interferon, streptokinase, GCSF, and interferon beta.

Largest Anti-Cancer Drug Production Plant in the Middle East: The Actoverco pharmaceutical group has launched nine production lines for anti-cancer drugs with an investment of over 100 million euros. This is the first German-American bioreactor in the Middle East with OFAC and BAFA licenses.

All products from these production lines are evaluated and controlled Actoverco's advanced quality control laboratories. These laboratories are equipped with the latest and most accurate analytical equipment, including 16 HPLC devices, seven UV and IR spectrophotometers, four TOC devices, and three GC devices.

Iran's Pharmaceutical Production: Iran ranks first in pharmaceutical production in the region. 97% of the country's needed medicines are produced domestically. Iran is now the fourth producer of recombinant drugs in Asia. So far, 14 such drugs have been produced in the country. Recombinant drugs are mainly used in the treatment of incurable diseases such as cancers, some viral diseases, multiple sclerosis, and hemophilia.

Medical Equipment: Iran has made significant strides in the development and production of medical equipment in recent years. This progress is driven by a combination of factors, including government investment, a growing knowledge-based economy, and the dedication of researchers and entrepreneurs. Iran has successfully produced image processing equipment for CT scan devices, a vital component for accurate medical imaging.

Medical Plants: Leaning on its rich history of herbal medicine, Iran is experiencing a resurgence in this field. The establishment of refineries for processing medicinal plants alongside the development of innovative extraction methods, like the tripling of rose essence yield, showcases this commitment. Furthermore, AI-powered machines are being built to improve the efficiency and quality of harvesting valuable saffron. This surge in research and development, coupled with the vast array of native medicinal plants in Iran, positions the country as a potential leader in the revitalization of traditional medicine.

Health Tourism: Leveraging its long history of medical excellence and world-class facilities, Iran's health tourism sector is booming. With 247 licensed medical centers catering to over 1.2 million medical tourists from 164 countries in 2023 alone, Iran has secured its place as a leading destination (ranking 46th globally). The recent establishment of two herbal refineries in Razavi Khorasan Province further strengthens this position by providing innovative treatment options, attracting even more international patients seeking high-quality healthcare.

Additional Areas of Focus: Iran is actively researching and developing cutting-edge solutions in areas like nanomedicine, advanced medical imaging, telemedicine, gene therapy, and tissue engineering. These advancements have the potential to revolutionize healthcare delivery, disease detection, and treatment options in Iran and beyond.

Iranian Government's Support for the Health Sector

The Iranian government has implemented a multi-faceted approach to support the growth and innovation of the domestic health industry.

A significant 52% increase in healthcare funding for the Ministry of Health and affiliated organizations was allocated in the 2023 budget. The government prioritizes strengthening infrastructure for the production of high-quality pharmaceuticals, vaccines, medical supplies, and equipment that meet international standards.

This focus aims to reduce reliance on imported medical products and potentially make healthcare more affordable. A specific support package has been developed to incentivize domestic production of medicines and health products. This initiative aims to reduce dependence on foreign imports and potentially lower healthcare costs for the population.

Recognizing the potential of the Iranian health industry, the government provides direct financial support to manufacturing companies to participate in and visit international health exhibitions. This initiative enhances visibility for Iranian healthcare products in the global market and potentially opens doors for export opportunities.

Pharmaceutical Industry in Iran

The pharmaceutical industry has always been one of the most important pillars of the health system in the world due to its impact on human health and human societies. Today, this industry is known as one of the key and strategic industries in the world, and having a high level of capability in this sector is considered one of the important criteria for the development of countries.

The Iranian pharmaceutical industry is one of the most key and strategic industries in the country. Iran boasts a well-established pharmaceutical industry with a rich history. As Pioneering Spirit, the foundation for this success was laid in the 1920s with the establishment of the Pasteur Institute of Iran.

This pioneering institution not only focused on vaccine production but also nurtured a culture of scientific research and development (R&D). This early emphasis on domestic capacity building continues to be a hallmark of the industry.

Over the years, Iran has emerged as a leading force in the Middle East and North Africa (MENA) region, achieving a high degree of self-sufficiency in medicine production.

Today, Iran's pharmaceutical sector is characterized by:


- **Strong Domestic Production:** Faced with external challenges, Iran embarked on a path of achieving self-sufficiency in pharmaceutical production. The industry manufactures a significant portion (around 90%) of medicines consumed within the country, catering to a wide range of therapeutic needs.
- **Advanced Capabilities:** Local manufacturers possess the expertise to produce complex generic drugs, including those for chronic diseases like diabetes and cancer. There's also a growing focus on biosimilars and other sophisticated treatments.
- **Skilled Workforce:** The industry is backed by a highly qualified pool of scientists, pharmacists, and researchers. This intellectual capital fuels continuous innovation and advancements in drug development.

An Overview of Iran's Pharmaceutical Industry

Iran currently manufactures 96% of the medicine for its population in numbers and 69.7% in terms of Value. 30% of drugs are brand name and 70% are generic. As can be seen in the diagram, the majority of Iran's pharmaceutical needs are supplied by domestic producers.



Exhibit 6: Iranian Pharmaceutical Industry at a Glance (Source: Due Diligence Helpdesk)



According to the SJR website's scientific ranking, Iran ranked 10th in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and 11th in Drug Discovery in 2022.

Statistics of Iran's Pharmaceutical Industry

- 114 Human drug factories
- 43 Raw material production and extraction factories
- 80 Registered pharmaceutical import companies
- 60 Nationwide distribution companies
- 180 Provincial distribution and wholesale companies
- 13052 Pharmacies in Iran

Iran's Pharmaceutical Market

According to the latest report published by Statista in 2024, Iran has seen a significant development in its Pharmaceuticals market in recent years. Iran's pharmaceutical market is experiencing a surge in domestic production and research, positioning the country as a key player in the Middle East. The reasons for this development are presented below:

Customer preferences: Iranians have become increasingly health-conscious and are now more inclined to use pharmaceutical products to treat their ailments. Customers are also more likely to purchase branded pharmaceutical products over generic ones due to a perception that branded products are of higher quality.

Trends in the market: The Iranian pharmaceuticals market has been growing at a steady pace in recent years. This growth can be attributed to several factors, including an increase in the country's population, an increase in the prevalence of chronic diseases, and an increase in government spending on healthcare. Additionally, the Iranian government has been working to reduce the country's reliance on imported pharmaceutical products by encouraging local production.

Local special circumstances: One of the unique aspects of the Iranian pharmaceuticals market is the country's reliance on local production. The Iranian government has been working to develop the local pharmaceutical industry in order to reduce the country's reliance on imported products. This has led to an increase in the number of domestic pharmaceutical companies and an increase in local production.

Underlying macroeconomic factors: The Iranian pharmaceuticals market is influenced by several macroeconomic factors. One of the most significant factors is the country's population growth. Iran has one of the largest populations in the Middle East, which has led to an increase in demand for pharmaceutical products.

Additionally, the prevalence of chronic diseases such as diabetes and cancer has been increasing in Iran, which has also contributed to the growth of the pharmaceuticals market. Finally, government spending on healthcare has been increasing in recent years, which has led to an increase in demand for pharmaceutical products.


Iran's pharmaceutical sector is undergoing a significant shift. While the country previously relied heavily on imports, averaging 2 to 2.5 billion USD annually for both finished drugs and raw materials, recent years have seen a growing emphasis on domestic production.

This is evidenced by the construction of new production plants, leading to a decline in finished product imports. Conversely, imports of raw materials for drug production have risen. This trend suggests Iran is increasingly sourcing the building blocks for its own medicines, fostering greater self-sufficiency in the pharmaceutical sector.

Exhibit 7 depicting the historical trend of drug and drug raw material imports into Iran is included for further reference.



Exhibit 7: The Value of Imported Raw Materials and Drugs to Iran (Source: Tehran Stock Exchange)




The Iranian pharmaceutical market is poised for significant growth in the coming years. According to Statista data published in 2024, the market is expected to reach a projected revenue of 7.90 billion USD in 2024.

This growth is fueled by several factors, including an increasing population, a growing prevalence of chronic diseases, and rising healthcare costs.

Oncology drugs are currently the largest segment within the market, with a projected market volume of 1.55 billion USD in 2024. This highlights the growing need for cancer treatment medications in Iran.

Additionally, the market is anticipated to exhibit a healthy annual growth rate of 5.8% (CAGR 2024-2028), which is expected to result in a market volume of 9.90 billion USD by 2028. This steady growth presents exciting opportunities for both domestic and international pharmaceutical companies.


Exhibit 8: Revenue of Pharmaceutical Products in Iran (Source: Statista)



Global Pharmaceutical Market

According to the latest global market report published by Mordor intelligence, the Pharmaceutical Manufacturing Market size is estimated at 465.16 billion USD in 2024, and is expected to reach 967.12 billion USD by 2029, growing at a CAGR of 12.14% during the forecast period (2024-2029).

Exhibit 9: Estimation of the Global Pharmaceutical Market (Source: Mordor Intelligence)




The global landscape of pharmaceutical manufacturing is experiencing a shift. While developed countries in Europe and North America continue to be major players, they are seeing average growth rates.

In contrast, regions like South Asia and Australia are witnessing a surge in this market, boasting the highest growth rates worldwide.

Iran stands out as a particularly bright spot. Not only does it hold the title of the fastest-growing pharmaceutical manufacturing market within the Middle East, but it also ranks among the global leaders in this impressive growth.

This exceptional performance suggests a thriving pharmaceutical sector in Iran, poised to play a significant role on the international stage.

Exhibit 10: Pharmaceutical Market-Growth Rate by Region (Source: Mordor Intelligence)



Iran's Innovation in Pharmaceutical Industry

Iranian scientists and companies have registered more than 80 patents in the field of pharmaceuticals in the European and US patent offices.

This is a significant achievement for the Iranian pharmaceutical industry, as it demonstrates the country's growing capabilities in this field. The patents cover a wide range of areas, including new drugs and drug delivery systems.

The registration of these patents in Europe and the United States is a testament to the quality of Iranian research and development in the pharmaceutical field. It also shows that Iranian companies are increasingly able to compete in the global market.

The registration of these patents is also likely to have a positive impact on the Iranian economy. It could lead to increased investment in the pharmaceutical industry, as well as the creation of new jobs.

High- Growth Opportunities

The pharmaceutical industry presents several high-growth opportunities driven by various factors, including technological advancements, evolving healthcare needs, and global market dynamics. Here are some high-growth opportunities in the pharmaceutical sector:

- **Biopharmaceuticals and Biologics:** The development and manufacturing of biopharmaceuticals, including monoclonal antibodies, gene therapies, and cell therapies, offer significant growth opportunities. These innovative treatments hold promise for various diseases, such as cancer, autoimmune disorders, and genetic conditions.
- **Personalized Medicine:** Advances in genomics, molecular diagnostics, and precision medicine are driving the growth of personalized medicine. Tailoring treatments based on an individual's genetic profile and characteristics can enhance efficacy and reduce adverse effects. The integration of biomarkers, companion diagnostics, and targeted therapies is transforming patient care and opening new avenues for pharmaceutical companies.
- **Digital Health and Telemedicine:** The convergence of healthcare and technology is creating opportunities for pharmaceutical companies to develop digital health solutions and leverage telemedicine platforms. Digital therapeutics, remote patient monitoring, and health apps are revolutionizing healthcare delivery, enhancing patient engagement, and enabling remote consultations.
- **Specialty Pharmaceuticals:** Specialty pharmaceuticals, including orphan drugs, biosimilars, and therapies for rare diseases, represent a high-growth segment. As the understanding of rare diseases improves and regulatory pathways become more favorable, the development and commercialization of specialized treatments present significant opportunities for pharmaceutical companies.
- **Immunotherapy and Oncology:** Immunotherapy has emerged as a game-changer in cancer treatment, harnessing the body's immune system to target and destroy cancer cells. With ongoing research and development in immuno-oncology, there are opportunities to develop innovative immunotherapies, combination therapies, and biomarker-driven treatments for various types of cancers.
- **Aging Population and Chronic Diseases:** The global increase in the aging population and the prevalence of chronic diseases such as cardiovascular diseases, diabetes, and neurodegenerative disorders create substantial growth opportunities for pharmaceutical companies. Developing innovative therapies to address the specific needs of these patient populations is a key focus area.
- **Emerging Therapeutic Areas:** Pharmaceutical companies are exploring emerging therapeutic areas such as regenerative medicine, gene editing, neurology, rare diseases, and infectious diseases. Breakthroughs in these fields have the potential to transform patient care and offer substantial growth opportunities for innovative companies.
- **Drug Repurposing and Drug Delivery Technologies:** Repurposing existing drugs for new indications and leveraging novel drug delivery technologies can expedite the development process and offer new revenue streams. Enhancing drug efficacy, improving patient compliance, and exploring novel delivery systems, such as nanotechnology and targeted drug delivery, are areas of significant interest.
- **Collaborations and Partnerships:** Collaboration among pharmaceutical companies, academic institutions, and research organizations is crucial for driving innovation and capitalizing on growth opportunities. Strategic partnerships, licensing agreements, and research collaborations can accelerate drug discovery, development, and commercialization.

SWOT Analysis



Strengths

Domestic production of medicine:

More than 90% of the medicine consumed in Iran is produced domestically. This reduces the country's dependence on imported medicine.

Variety of medicine:

Iranian pharmaceutical companies produce a wide variety of medicine in different forms. This ensures that patients have access to the medicine they need.

Modernization of facilities:

Iranian pharmaceutical facilities are being modernized to improve efficiency and quality.

Skilled workforce: Iran has a well-educated and skilled workforce, including professionals in various fields related to pharmaceuticals.

Government backing:

The Iranian government prioritizes self-sufficiency in pharmaceutical production through policies and investments in R&D.

Decades of Experience:

Iran boasts a well-established pharmaceutical industry with a rich history of knowledge and experience.

Manufacturing Capacity:

Despite potential limitations in certain areas, Iran has a growing manufacturing capacity for a variety of pharmaceuticals.

Cost-Effective Production:

Iranian-produced pharmaceuticals can be a cost-effective option for both Iranian and international markets due to lower production costs compared to some international markets.



Weaknesses

Limited Access to Technology and Resources:

International sanctions can restrict access to advanced technologies, equipment, and raw materials necessary for modern pharmaceutical production.

Currency Fluctuations:

Sanctions and political instability can create unpredictable currency fluctuations. This makes it difficult for Iranian companies to import necessary materials.

Aging Infrastructure:

Some parts of Iran's pharmaceutical infrastructure, including manufacturing facilities and research laboratories, may require modernization to meet international quality standards.

Limited Research and Development Funding:

While R&D is crucial for long-term growth, its funding may be limited compared to international competitors. This can hinder the development of innovative new drugs and technologies in Iran.



Opportunities

High Market Growth:

Iran's pharmaceutical market is experiencing significant growth, projected to reach USD9.90 billion by 2028 (according to Statista data published in 2024).

Large and Growing Population:

Iran's sizable and growing population of over 85 million creates a substantial and increasing demand for high-quality pharmaceuticals.

Technological Advancement:

Partnering with established Iranian companies can offer access to their knowledge base while facilitating the transfer of cutting-edge technologies and expertise.

Joint Research and Development:

Combining resources for R&D allows companies to leverage Iran's growing pool of scientific talent and research institutions.

Regional Hub:

Iran's strategic location positions it well to become a regional hub for pharmaceutical exports.

Government Support:

The Iranian government actively supports domestic pharmaceutical production and offers incentives for foreign investment. This translates to potential tax benefits and streamlined regulatory processes for collaborative ventures.

Threats

Limited Access to Advanced Technologies:

Despite progress in domestic production, access to cutting-edge technologies and high-end equipment might be hindered by sanctions or limitations in specific areas.

Dependency on Raw Materials:

Iran may rely on imports for some essential raw materials needed for pharmaceutical manufacturing. This can create vulnerabilities in supply chains.

Research and Development Investments:

While R&D is a growing focus, continued investment is needed to foster innovation and compete on the global stage. Collaboration with international partners can provide access to expertise, funding, and resources needed to develop novel drugs and treatments.

Limited Brand Recognition:

Iranian pharmaceutical companies may have limited brand recognition globally, hindering their ability to compete effectively in international markets.

Streamlining Regulatory Processes:

Streamlining and harmonizing regulatory processes can potentially expedite drug approval times and attract foreign investment.

International Regulatory Frameworks

A quality management system (QMS) in pharmaceuticals is a set of processes and methods that are used to achieve defined quality objectives. Part of these objectives relate to the effectiveness of the drug for treatment. By using a strong quality management system, pharmaceutical companies can reduce potential risks, increase customer satisfaction, and simplify quality assurance processes. Some of the most common standards and regulations defined in pharmaceutical QMS include the following:

ISO Standards in Pharmaceuticals

ISO standards in pharmaceuticals refer to a set of procedures, guidelines, and policies that are developed and implemented to ensure the quality, safety, and efficacy of drugs and pharmaceutical products.

These standards are developed and published by the International Organization for Standardization (ISO) and are used as general guidelines in the pharmaceutical industry. These standards include:

- **ISO 15378:** Packaging of pharmaceutical excipients- ISO 15378:2017 is an application standard for the design, manufacture, and supply of primary packaging materials for medicinal products.
- **ISO 9001:** Quality management in the pharmaceutical industry- ISO 9001 is an international standard that is relevant to quality management in all industries, including the pharmaceutical industry. The aim of this standard is to ensure the quality of products and services in organizations. ISO 9001 is based on a «process» approach and emphasizes physical tablet testing, interaction between different processes, and continuous improvement of product and service quality.
- **ISO 17025:** Competence of testing and calibration laboratories- ISO/IEC 17025 is the international standard for testing and calibration laboratories. It sets out requirements for the competence, impartiality, and consistent operation of laboratories, ensuring the accuracy and reliability of their testing and calibration results.



- **ISO 14001:** Environmental management in the medical and pharmaceutical industry- ISO 14001 is an international standard that is relevant to environmental management in all industries, including the medical and pharmaceutical industry. The aim of this standard is to reduce the negative environmental impacts of industrial activities and improve the environmental performance of organizations. ISO 14001 is based on the «environmental management system» (EMS) approach and emphasizes the interaction between different processes and continuous improvement of environmental performance.

ICH Q10 Guideline

The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an association that operates under Swiss law. The main objective of this association is to further harmonize pharmaceutical requirements worldwide.

The letter Q next to different numbers identifies the type of quality guidelines. For example, Q10 is a guideline that is used for quality management in the pharmaceutical industry.

Current Good Manufacturing Practice (cGMP)

Current Good Manufacturing Practices (cGMP) are regulations defined by the U.S. Food and Drug Administration (FDA), which is responsible for the production of safe drugs. Based on these regulations, the quantity, quality, and purpose must be determined at the time of product production, and ultimately, compounds must be produced that are free of any contamination

The European Union (EU) legal framework for pharmaceuticals

The European Union (EU) has a comprehensive legal framework governing the authorization, manufacture, and distribution of medicines. Three key regulations form the foundation of this system:

- **Regulation (EU) No 20196/:** This is the primary legislation outlining the overall framework for all medicines in the EU.
- **Regulation (EC) No 7262004/:** This regulation likely delves deeper into specific aspects of the general framework established by Regulation (EU) No 20196/.
- **Directive 200183//EC:** This directive complements the regulations by addressing related areas within the pharmaceutical legal landscape.

The EU framework additionally defines specific categories of medicines with their own regulations:

- **Paediatric Medicines:** Regulation (EC) No 19012006/ ensures the safety and efficacy of medicines specifically designed for children.
- **Advanced-Therapy Medicines:** Regulation (EC) No 13942007/ establishes the legal framework for innovative treatments like gene therapy and tissue engineering, amending existing regulations to accommodate their unique characteristics.
- **Orphan Medicines:** Regulation (EC) No 1412000/ facilitates the development and market access of treatments for rare diseases that affect a small patient population.
- **Traditional Herbal Medicines:** Directive 200424//EC governs this sector, ensuring the safety, quality, and efficacy of these traditionally used remedies.

Some Iranian Prominent Companies in Pharmaceutical Industry

CinnaGen Company

Brief Overview

CinnaGen Pharmaceutical Group was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Today the company produces more than 100 different products and is the biggest bio-pharmaceutical manufacturer and biotech exporter in the region.

Products

Cinnagen's product portfolio is divided into four main groups, which include: Neurology & Ophthalmology, Oncology & Hematology, Endocrinology & infertility, and Autoimmune & Immunology.

Industrial Achievements and Export

- This group has eight subsidiary companies and five manufacturing sites that obtain GMP certification from the European Union.
- CinnaGen allocates and invests big part of its annual revenue in R&D (about 20%) to achieve new biopharmaceutical drug
- The company have constructive scientific partnership and collaboration with Fraunhofer institute (Germany), Boku University (Austria), British Columbia University (Canada), UGA Biopharma (Germany), Medical university of Tehran (Iran), Shahid Beheshti medical University (Iran) and other several research institutes.
- CinnaGen is the biggest exporter of biotech products in Iran and the middle-east
- CinnaGen ilac has been established in 2019 and this company is the first full cycle manufacturing site to produce biosimilars in Turkey.
- CinnaGen is the biggest exporter of biotech products in Iran and the middle-east
- CinnaGen ilac has been established in 2019 and this company is the first full cycle manufacturing site to produce biosimilars in Turkey.

Certificates & Standards

- Integrated management system (IMS) in compliance with
- ISO 9001:2015
- ISO 14001:2015
- OHSAS 18001:2007
- ISO10015:1999
- ISO 10002:2014



www.cinnagen.com



cinnagen@cinnagen.com



+98 21 42815



+98 21 88561575

AryoGen Pharmed Company

Brief Overview

Established in 2010 by well experienced scientists, AryoGen Pharmed pharmaceutical company has focused on providing biopharmaceutical products meeting world standards. The production facility is configured to manufacture some of the latest biopharmaceutical compounds to hit the local and international markets.

Products

AryoGen is producing biosimilar or biogeneric form of some vital medicines that are critical for treatment of following diseases: Hemophilia A or B with inhibitors, Acquired hemophilia, Congenital, factor VII deficiency, Glanzmann's thrombasthenia, Breast cancer, Rheumatoid Arthritis, Arthritis, Spondyloarthritis, Plaque Psoriasis, Juvenile Idiopathic, Non-Hodgkin's Lymphoma, Juvenile Idiopathic, Chronic Lymphocytic Leukemia (ccl).

Industrial Achievements and Export

- It has exported the products to 21 countries all over the world.
- AryoGen Pharmed pharmaceutical company was selected as the Top Exporter of Iran in the years 2016, 2018, and 2022.
- The company received the statue of the Top Knowledge-based Export Company with five-stars and the statue of the export company with a significant leap in the year 2022.

Certificates & Standards

- This company has implemented and maintains a Quality Management System for the following scope:
- Development and production of biosimilar pharmaceutical recombinant proteins and monoclonal antibodies
- Further clarifications regarding the applicability of ISO 2025-9001:2015 requirements.



www.aryogen.com



contact@aryogen.com



+98 26 36106480 - 4

Pooyesh Darou Biopharmaceuticals Company

Brief Overview

Founded in 1997, Pooyesh Darou Pharmaceuticals today is one of the most well established biotechnology companies through the Middle East. With 6 recombinant biopharmaceutical products helping patients in the country, it became regional leader in the effort to develop and apply the most advanced capabilities in biotechnology to address a range of unmet medical needs. The company sterile manufacturing facility includes an 11000 sq. ft. production site. Their aseptic fill and finish manufacturing facilities are capable of filling over 13 million low volumes parenteral sterile unit per year and utilizes five high-speed filling lines and two lyophilizers.

Products

- **API Products:** GENERIC NAME, interferon alfa-2b, filgrastim, erythropoietin, peginterferon alfa-2a, pegfilgrastim, interferon alfa-2a
- **PIPELINE:** erythropoietin, Peg-erythropoietin, Human menopausal gonadotrophin Human Chorionic gonadotrophin, Somatropin, streptokinase, Follicle stimulating hormone, Interferon beta-1a, Peg-Interferon beta-1a

Industrial Achievements and Export

- Pooyesh Darou Pharmaceuticals has acquired technology exclusively from the ICGEB (United Nations' International Center for Genetic Engineering and Biotechnology, Trieste-ITALY) to manufacture recombinant-DNA-based therapeutic proteins, the endogenous hormones and leukotriene that control essential body functions. The company is the first in Iran to use these genetically modified bacteria and cells to produce basic endogenous proteins.
- The company collaborates with the best experts in the fields such as ICGEB in Trieste-ITALY, Primm labs (GLP certified laboratory) in Milan-ITALY and the National Institute for Biological Standards and Control (NIBSC) in London-UK.
- Pooyesh Darou Pharmaceuticals manufacturing spaces' elements such as building materials, space design, facilities and flows, have considered all the environmental regulations and meet all quality criteria for manufacturing biological products.
- Pooyesh Darou Pharmaceuticals' QC laboratories are equipped with all necessary reagents and equipment to perform complete QC tests for biological products.

Certificates & Standards

- The Aseptic Manufacturing Facility of company maintains a static and operational Grade A (ISO Class 5) environment.
- Their production site meets and exceeds standards for ISO 9001:2008, ISO OHSAS, 18001:2007 and ISO 14001:2004.



www.pooyeshdarou.com



info@pooyeshdarou.com



+98 21 88 997 248

ExirNanoSina Company

Brief Overview

ExirNanoSina is a knowledge based company founded in 2011 with the support of Iran Nanotechnology Initiative Council. Researches at this company are mostly focused on formulation based on nano-liposomes and nano-micelles using lipids and surfactants to improve the pharmacokinetic of the drugs, with industrial production vision for parenteral, oral and topical applications.

Products/Services

- ExirNanoSina offers various new drug delivery systems such as liposomes and micelles.
- SinaDoxosome®
- SinaAmpholeish®
- SinaLiv®
- SinaCurcumin®

Industrial Achievements and Export

- This company produces high-quality nano-liposomal and nano-micellar products by experienced scientists using the highest quality lipids material and advanced technology platform.
- ExirNanoSina Co. with the help of nanomedicine can develop liposomal/ micellar formulation of medicines at the nanometer scale, enhancing drug solubility, protecting molecules from degradation, or targeting drug delivery to specific tissues, and creating drugs with higher half-life with increased efficacy.



www.ens.co.ir



info@ens.co.ir



+982188223260



+982188632687

Tofigh Daru Research & Engineering Company

Brief Overview

Tofigh Daru Research and Engineering Company (TODACO) was initially founded in 2000 to develop the know-how of API (Active Pharmaceutical Ingredient), FDF (Finished Dosage Form) and executing the construction of relevant plants. In 2003, it started to be known as the manufacturing organization of high-tech APIs and currently is known for its prime position in this segment by developing newly-approved molecules on the cutting-edge of science.

Products

TODA's product portfolio is divided into four main groups, which include:

- Immunomodulatory agents
- Endocrine system
- Cardiovascular
- Narcotic
- Peptide
- Anticancer
- Antiviral Agents

Industrial Achievements and Export

Utilizing the full capacity of its 6 different GMP-approved production lines, Todaco has accomplished to produce API of 48 different molecules.

This company takes advantage of modern facilities in Microbiologic tests: Quantitative detection of Endotoxin, sterility test, colony count; and Physicochemical tests using Polarimeter, Potentiometer, TLC Scanner, KF, Atomic Absorption, HPLC Equipped with PDA, RI, UV and fluorescence detectors, GC, GC MS.

Physicochemical tests using Polarimeter, Potentiometer, TLC Scanner, KF, Atomic Absorption, HPLC Equipped with PDA, RI, UV and fluorescence detectors, GC, GC MS

Certificates & Standards

- Acquired MOH accreditation for quality control of food and cosmetic products in ,2010 2016 ,2015.



www.todaco.com



info@TODACO.com



+982144988020 - 4



+982144985056

ExirNanoSina Company

Brief Overview

ZistDaru Danesh is a private and knowledge-based group that is active in the field of production and marketing of chemical and biological medicinal products. This company was established in 2004. Since 2013, Bio-Daru Danesh started the construction of a factory for the production of pharmaceutical products in Baharestan Karaj Industrial City, and since 2015, the production of Zifron and Tebazio products has continued with the establishment of the factory at the new site.

Products/Services

Neurology:

- MS: ZIFERON, GLATZI, TECZIFUMA, TEBAZIO
- ALS: ALSAVA

Oncology:

- ZIVEK
- ERLOXHA

Others:

- TOFAXHA
- ZISTINE
- PIRFENZI
- FERRIRISE

Industrial Achievements and Export

- This company currently has 4 separate production lines, including the production line of recombinant proteins using bacteria, the production line of monoclonal antibodies, the line of vial filling and lyophilization, the production line of high-risk food products are operating.
- The research and development unit of Danesh Biomedicine Company is active in the field of cancer drugs and MS, including biosimilars and new drugs with low molecular weight.
- Zistdaru Daru company was selected as the Top Exporter of Iran in the years 2019

Certificates & Standards

- The pharmaceutical production plant of Zistaroo Danesh Company adheres to strict GMP protocols.



www.zistdaru.com



info@zistdaru.ir



+982148241000



+982142318123

Varian Farmad Company

Brief Overview

Varian Farmad Company started in 2009. Production of products on par with foreign products and at competitive prices has always been the focus of this company. Varian Pharmed is the second largest pharmaceutical company in the world with In Situ Forming technology. This system is one of the most advanced methods of drug delivery. Varian Pharmed is the first and only maker of this drug with this type of technology in the world by patenting the manufacture of tryptoroline acetate with in Situ Forming technology.

Products

- **Diabetes medications:** VARIOMET ER(Extended Release metformin), LINOGLUCO, EMPAGLUCCO, METJAN, EMZIP, LIMETA, Jarlino
- **Oncology:** Vario-mitexan, Leupromer, Zol-var, Variopeptyl
- **Women:** Variopeptyl, Leupromer
- **Pain killer:** Pyromol
- **Pediatric glands:** Variopeptyl 0.1 mg, Leupromer 3.75 and 7.5 mg
- **General:** VARIOCOLD

Industrial Achievements and Export

- This company, taking advantage of the power of specialists and technologists, in addition to responding to the pharmaceutical needs of the country, has the possibility of exporting pharmaceutical products and technical knowledge to other countries.
- In-situ forming pharmacy systems used by this company have numerous benefits, including delivering hazardous drugs such as anti-cancer drugs and reducing the administration times to once a month or even once every three months. Better therapeutic results, stability of the drug in the patient's blood during treatment, reducing side effects and the need to visit healthcare providers, the atmosphere of clinics and remembrance of the disease, lowering the chance of chronic diseases in hospitals, and administration errors are significant benefits of these systems.

Certificates & Standards

- One of the technologies developed by Varian Pharmed's research team is in-situ forming technology, which was approved by the US. FDA.



www.varianpharmed.com



info@varianpharmed.com



+982144004051

Temad Company

Brief Overview

Temad Co. was established in 1997 and is one of the largest producers of APIs in Iran and innovative manufacturer of Narcotics and Non-narcotics in two main categories of Active Pharmaceutical Ingredients (API) and semi-finished; pellet and DC in the Middle East. In order to develop business by considering the export markets, Temad Co. started planning to produce Finished dosage products, kinds of Syrup, Tablets and Capsule from 2017 to achieve the most Narcotics and Non-narcotics market share to supply to domestic pharmaceutical companies and Middle East.

Products/Services

- This company has more than 120 pharmaceutical products including narcotics and general APIs in different forms such as DC grade API, pellets and non-sterile injectable grade.

Industrial Achievements and Export

- At present, the company has 21 active production lines (10 lines of Alborz site and 11 lines of Mashhad site) and more than 120 kinds of pharmaceutical products including narcotics, non-narcotics, LVHV, corton, injections, medicine for opioid dependency; Buprenorphine Table 2 mg, Methadone Tablets 20 and 40 mg, Methadone syrup, Opium syrup 1%, Guaicodin syrup and Pellet products that are controlled and evaluated according to the standards of GMP and terms of WHO in the field of pharmaceuticals products based on international standards USP,BP,EP,IP and JP.
- The company supplies its products to all around of Iran as a domestic market and also exports 26 products to more than 56 countries in 6 continents, therefore having effective presence as one of the international competitors, has significant role in supplying pharmaceutical materials and narcotics in the global markets.

Certificates & Standards

- ISO 5001:2018
- ISO 9001:2015
- ISO 14001:2015
- ISO 10015:2019



www.temad.com

temad@temad.com

+98 2636161118

Dorsa Pharma Company

Brief Overview

Dorsa Pharmaceutical Company established in 1998 and is a progressive manufacturing entity that specializes in high-quality generic drugs, APIs, biosimilar, and pharmaceutical products. The company is accredited by Vice-Presidency office for Science and Technology and is the holder of grade <A> GMP certificate by Iran FDA, which is a member of PIC/S.

Products

- **Finished products:** Supplements, Nervous System, Musculo-skeletal, Respiratory, Antibiotics, Biosimilar, Cardiovascular, Alimentary tract, Urology, TNG Bulk, 3ply, mask
- **Semi-Finished Product:** Nitroglycerin 0.35% In Miglyol, Nitroglycerin 5% In Ethanol, Nitroglycerin 5% In Propylene Glycol, Nitroglycerin 5% In Miglyol, Nitroglycerin Granules 1.6%
- **Biosimilars:** Epolyrec®, Gammarec®

Certificates & Standards

- This company has obtained a grade <A> GMP certificate from Iran FDA for all their production sites
- ISO 9001:2015
- OHSAS 18001:2007
- EN ISO 14001:2004
- ISO 9001:2008



www.dorsapharma.com



info@dorsadarou.com



+982154612000

Temad Company

Brief Overview

Exir Pharmaceutical Company is one of the largest and most advanced pharmaceutical manufacturers established in 1988. The factory currently produces more than 160 pharmaceuticals in various dosages and administration forms ready for the consumer market. The company products include pharmaceutical finished forms in various forms; tablets, capsules, ampoules, cartridges, syrups and powder for oral suspension and injectable vials.

Products/Services

- The factory currently produces more than 160 pharmaceuticals in various dosages and administration forms, which are divided into 13 main groups including: Anticoagulant agent, Supplements & Vitamines, Diabetes, Immunomodulator, Renal, Antibiotics, gastrointestinal, Respiratory, Neurologic, Psychiatric, Antidotes, Common Cold, Cardiovascular, Hormone, cancer, Hematopoietic agent.

Industrial Achievements and Export

- The company exports its products to more than 18 countries, including Ukraine, Afghanistan, Yemen, the Philippines, Azerbaijan, Tajikistan, Iraq, Syria, Somalia, Sri Lanka, Uganda, Lebanon and Armenia which has honored Exir as the premier Exporter of the country for six years and has been chosen as the top exporter in this field.

Certificates & Standards

- All the processes are designed and performed in accordance to GMP standards and WHO rules.
- ISO 9001 for Quality Management System, ISO 14001 for Environmental Management, ISO 18001 OHSAS for Occupational Health and Safety System



-  www.exir.co.ir
-  info@exir.co.ir
-  +982144983395
-  +982144984695

Varian Farmad Company

Brief Overview

Aburaihan Pharmaceutical company was founded in 1965. The company has been among top ten Iran pharmaceutical manufacturers in the last decades and the most important one in Hormonal medicines. Aburaihan has also been one of the greatest manufacturers of Veterinary medicines since 1991.

The company manufactures all its products according to international standards.

Products

production of drugs in the field of : Allergy, Immunology and Rheumatology, Anesthesia, Veterinary Medicine, Hematology & Oncology, Neurology, Cardiovascular, Endocrinology and Metabolism, Gastrointestinal, Women's Health, Sex Hormones, Respiratory, and etc.

Industrial Achievements and Export

The products are being registered and exported to Asian countries (Iraq, Afghanistan, Lebanon, Yemen, Thailand, Syria, Sri Lanka, Myanmar, Vietnam), CIS countries (Tajikistan, Uzbekistan, Kazakhstan, Ukraine, Azerbaijan, Georgia) and African countries (Uganda).

Certificates & Standards

- ISO 9001:2015
- ISO 10015:1999
- ISO 45001:2018
- ISO 14001:2015



www.aburaihan.com



info@aburaihan.com



+98 21 77707173 - 6

References

- Due Diligence Helpdesk on EU Sanctions for EU SMEs dealing with Iran. (2022). <https://sanctions-helpdesk.eu/>
- Electro Farmed Azin Gostar Co. (1402). Principles of quality management in the pharmaceutical industry. <https://electrofarmed.com/>
- European Medicines Agency. (2023). <https://www.ema.europa.eu/>
- ISO (International Organization for Standardization). (2023). <https://www.iso.org/>
- Karisma Financial Group. (1402). Fundamental analysis: a comprehensive review of the pharmaceutical industry. <https://learning.charisma.ir/>
- Markets and Markets. (2023). Pharmaceuticals Market Research Reports & Consulting. <https://www.marketsandmarkets.com/>
- Mordor Intelligence Market Research Company. (2024). <https://www.mordorintelligence.com/>
- NQA. Global Certification Body. (2023). <https://www.nqa.com/>
- Pasargad Bank Brokerage Company. (2015). Review and analysis of the pharmaceutical industry. Iran Health Economy Federation. <https://ifoeh.com/>
- SCImago, (n.d.). SJR — SCImago Journal & Country Rank. (2022). <http://www.scimagojr.com>
- Skini, Ali, Haqgou, Mehrdad. (1402). Review of the pharmaceutical industry. Bourse Magazine. <https://tsemag.ir/>
- Statista. (2024). <https://www.statista.com/>



BEYOND POTENTIAL

The Realities and Future of Iran's
Pharmaceutical Industry